Search Results
Effects of increased interstitial pressure on venous distension reflex
The purpose of this study is determine if an increase in interstitial pressure has an effect on the venous distension reflex.
This study involves a single visit with 2 trials.You will receive an infusion of saline in your arm before and after a procedure to cause a temporary swelling in your arm.
You will receive $25 per hour for your participation in this research study
Healthy (no major disease)
Between 21-60 years old
Weigh over 110 punds
Pregnant or nursing women
Have a major disease (heart, lungs, kidney, diabetes, cancer)
High blood pressure
Student Housing Assessment
The primary objectives are to identify why students choose where they live; what is their perception of value for housing; is this value based on their home city/state/country; how are they paying for housing costs; if their parents are paying for the housing, what perception of value do the parents have, what is their economic status, what is their home owning status, etc.
Graduate Student
Enrolled and living at University Park
Functional magnetic resonance imaging (fMRI) and psychophysical studies of sensory perception and cognition
The purpose of this study is (1) to understand how the brain processes sensory information and (2) how this is affected by factors like blindness or synesthesia. In addition to behavioral testing, the study will use functional magnetic resonance imaging (fMRI) which enables us to take pictures of the brain while you are doing a task, using an instrument called an MRI scanner.
Participants will perform simple behavioral tasks either stand-alone or while being scanned; they may also complete questionnaires or rating scales.
Amount varies depending on the study
Normal or corrected-to-normal vision
No other sensory deficits
Adults who experience synesthesia
Must pass MRI safety screen (if applicable)
Minors under the age of 18
Individuals who fail the MRI safety screen (may still do behavioral studies)
Trust in Machine Agents Under Realistic Threat
Measures of actual human-machine interaction are required to generate ecologically valid, translatable discoveries that enhance human-systems integration and performance. Here, the proposed methods center on human-robot decision tasks to assess key determinants of human trust in robot recommendations (e.g., factors such as threat-salience and/or robot appearance), and the concomitant impacts of trust on performance.
There will be one in person visit, you will be asked to interact with a robot in a virtual environment.
10
Must not be suffering from anxiety disorders and/or panic attacks.
Must not be suffering from any known heart conditions.
Must not, to your knowledge, be prone to nausea when experiencing VR
Suffers from anxiety disorders, suffers from heart conditions, prone to nausea when experiencing VR
Identification of Emotion in Music in Autism Spectrum Disorders
The purpose of the project is to learn more about reactions to music by adults with and without autism spectrum disorders. Participants will listen to short pieces of music and answer some questions on a computer. They will also complete some formal testing and answer some interview questions.
Normal or corrected to normal vision
Normal hearing
Individuals with and without an autism spectrum disorder or Asperger syndrome
Willing to consent and complete study requirements
Vision problems (uncorrected)
Hearing problems
Significant learning problems
Unwilling to consent or complete study requirements
Comparing Interactions Between Heterogeneous and Homogeneous Pairs of Building Designers
This study considers how building designers work together on a design task. During the 1-hour long study, participants will be assigned a design partner and given a design task with specific goals to address. The entire study will take place over a computer and the design process will be recorded through the computer's video and audio.
Architectural Engineering Students
4th or 5th year undergrads with internship experience
Graduate students
A Phase I, Single-Center, Double-Blind, Randomized Safety, Tolerability, and Dermal Reactogenicity Study of Higher Doses of PDC-APB in Healthy Volunteers With a History of Contact Dermatitis Due to Poison Ivy Exposure
Phase 1, Double- Blind Study, 15 week study, Patch test and Vaccine Injection, Males/Females 18-65 years old with history of urushiol exposure. The rash or allergic contact dermatitis of poison ivy is recognized as occurring after the exposure to the urushiol oil which is found in the leaves of poison ivy, oak and sumac. Currently there is no preventative treatment for contact dermatitis. The purpose of this study is to find out if the vaccine, PDC-APB can help with the prevention of contact dermatitis.
Willing to follow all study instructions
Attend all study visits
Positive test result of HIV, Hepatitis B or Hepatitis C
Participation in an investigational drug or device study within 30 days prior to screening
There are over the counter medications that are not permitted during the study participation, the study coordinator will discuss the list during the screening process.
Exploring Parental Influence in Youth Disability Sport Participation
We are conducting an online survey study for parents of children with disabilities that explores their perceptions of participation in disability sport within their communities.
has a child that is enrolled in a disability or adapted sport program
has a child between the ages of 10 and 17
does not have a child with a disability between the ages of 10 and 17
does not have a child that plays a disability or adapted sport
Understanding the Well-being of Advanced Counseling Students of Color
The primary objective of this study is to increase our understanding of the ways in which perceived discrimination, coping strategies, competence, stress, social support, and self-efficacy in counselor education programs relate to overall well-being for advanced counseling students of color.
18 years of age or older
Capable of providing informed consent without the assistance of a legal guardian
Identify as a racial or ethnic minority
Able to understand written and spoken English at the time of the survey
Individuals who are not yet adults (infants, children, teenagers)
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
This Phase 1 and 2 study is to determine the safety of APL-101 in subjects with NSCLC with specific mutations. It is also to determine the dose that is tolerable for oral administration of APL-101. And to see if there is a clinical benefit to subjects for the amount of time to progression, or progression free survival and overall survival.
We are asking you to give permission for your doctor to send your stored tumor tissue sample for cancer genetic analysis. As part of your cancer care, your doctor may have already collected a tumor tissue biopsy sample (of your cancer tissue) in the past, recently, or being planned as part of standard medical care. Your doctor will ask for any of your stored or available tumor tissue sample collected elsewhere from previous doctors you may have seen in the past. We will not ask you to undergo a new tissue biopsy procedure for this testing however your treating physician may decide to do so as part of your standard of care.There is no required visit for this testing. Once you have signed this consent, your available tumor tissue sample from a prior biopsy or surgery along with the pathology report will be sent to an accredited and certified external genetic laboratory (such as Caris Life Sciences or Interpace Pharma Solutions) to test and understand your cancer’s genetic make-up. The use of your tumor tissue samples as described in this form is necessary for the genetic testing. Without your consent to test your samples, the genetic testing cannot be performed. Once you agree to provide your samples, they cannot be returned to your doctor’s clinic. If the genetic testing of your samples show you have c-MET genetic dysregulations in your cancer, your doctor will discuss your treatment options including clinical trials, such as the APL-101-01 SPARTA trial, with you. If you are interested in participating, you will be asked to review and sign another participant information and informed consent form for the clinical trial before undergoing further screening tests to confirm if you are eligible to participate. The genetic results could also be used to help your clinic doctor decide on an approved therapy, or other investigational therapies that may be right for your specific cancer genetic alterations.
Women of child-bearing potential (WOCBP) must have a negative serum or β-human chorionic gonadotropin (β-hCG) at screening or evidence of surgical sterility or evidence of postmenopausal status.
Abnormal c-Met dysregulation, by tissue and/or plasma, defined as the following from local/archival molecular pre-screening evaluations.
Measurable disease according to RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0–1
Known mutation/gene rearrangement of EGFR (except for Cohort C), ALK, ROS1, RET, NTRK, KRAS, and BRAF.
Active uncontrolled systemic bacterial, viral, or fungal infection or clinically significant, active disease process
History of, or currently, or at risk for, cardiac disease (e.g., long QT syndrome [> 450 msec QTcF or concurrent treatment with any medication that prolongs QT interval).
Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter drug absorption (e.g., Crohn’s, ulcerative colitis, active inflammatory bowel disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption sydrome).
PSCI# 18-127 EA6174 Adjuvant MK-3475 to SOC
The purpose of this Phase III study is to compare Overall Survival (OS) and Recurrence Free Survival (RFS) across the two arms: MK3475 (Pembrolizumab) to Standard of Care Observation. Patients will undergo standard clinical procedures including physical, labs, vitals, ecg's, and imaging.
We are asking you to take part in a research study. We do research studies to try to answer questions about how to prevent, diagnose, and treat diseases like cancer.
Patient must have a histological confirmation of diagnosis of Merkel cell carcinoma (MCC), pathologic stages (AJCC version 8) I-IIIb.
completely resected by surgery within 8 weeks before enrollment.
All patients must have disease-free status documented by a complete physical examination and conventional imaging studies within 4 weeks prior to randomization.
Patients must not be on active immunosuppression, have a history of life threating virus, have had other cancer diagnoses in the last two years
present metastases
previous systemic therapy or radiation therapy for Merkel cell carcinoma.
inoperable disease who have received radiation are not eligible.
history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
PSCI-22-042: M23-362 Epcoritamab monotherapy R/R DLBCL or Classic FL (Previously Grade 1-3a) outpatient
The purpose of this voluntary research study is to optimize the approach to safely administer a study drug called epcoritamab in the outpatient/non-hospital setting.
Complete interview, questionnaires, and subject diaryECGClinical laboratory testsBiopsy sample, archival or freshCT/PET-CT/MRITreatment of epcoritamab
Adult male or female, at least 18 years old
Diagnosis of R/R DLBCL or R/R FL grade 1, 2, or 3a, with documented CD20+ mature B-cell neoplasm according to WHO classification 2016 or WHO classification 2008 based on representative pathology report
Subject must have 1 or more measurable disease sites: Fluorodeoxyglucose (FDG)-avid lymphomas:
Subject must have Eastern Cooperative Oncology Group (ECOG) performance status 0 – 2
inadequate organ functions
central nervous system involvement
history of primary mediastinal lymphoma.
history of severe allergic or anaphylactic reactions to anti-CD20 monoclonal antibody therapy.
A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
The purpose of this voluntary research study is to learn more about treatment with an experimental drug called AZD9833 in combination with palbociclib. Participants will be required to follow your study doctor’s instructions, come to the study visits, take the study medications, and have the tests and examinations.
Participants will be required to: attend in person visitsreceive study treatmentradiology assessmentsblood testscomplete questionnaireshave an eye examhave a tumour biopsy
Evidence of a personally signed and dated informed consent document indicating that the patient (or legal representative) has been informed of all pertinent aspects of the study before any study-specific activity is performed.
Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of sample for optional genetic research that supports Genomic Initiative (as allowed per local regulations).
Female or male, ≥ 18 years at the time of screening.
Histologically or cytologically documented diagnosis of ER+, HER2-negative breast cancer based on local laboratory results and who are not amenable to resection or radiation therapy with curative intent.
Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral oedema, and/or progressive growth.
History of another primary malignancy except for the following: • Malignancy treated with curative intent with no known active disease ≥ 3 years before the first dose of study treatment, and of very low potential risk for recurrence.
As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including renal transplant and active bleeding diseases)
Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings,
Dysgeusia and Anosmia in Head and Neck Cancer Patients: Long Term Outcomes
The primary aim of this study is to understand taste changes after head and neck cancer treatment, especially long term taste disturbance, using various methods including online surveys, Teams interviews, at home taste and smell tests, and MRIs.
The purpose of this voluntary research study is to identify taste changes in patients treated for head and neck cancer. We are recruiting healthy participants over the age of 40 as well as head and neck cancer survivors who were treated 4 or more years ago. The overall study consists of multiple parts, which are explained along the way. You can choose to participate in this portion, which is an online survey, and nothing else, or all of the invited components. •The survey will take approximately 10 minutes of your time. •Completion of this survey is voluntary and you are not required to complete it if you do not wish to do so.•At the end of the survey you will be asked about your willingness to participate in other portions of this study. These include at-home taste and smell tests over Teams and a Teams interview about your taste and smell function. Participating in these tasks is optional and not required. If you complete the smell and taste tests at home you may be invited to have an MRI scan.
Max of $75: No compensation for the survey, $15 giftcard for 1-hour interview (optional), $15 giftcard for at-home taste/smell tests (optional), $50 giftcard for MRI at Hershey Med Center (optional).
Over the age of 40
English Speaking
have undergone a total glossectomy
currently have an upper respiratory infection, sinus infection, or ear infection
A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab.
Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype.
You will receive either study drug or placebo, undergo research-related tests and procedures, and questionnaires. You will need to visit the study center up to 18 times over a period of 15 months. You will have different tests and procedures throughout the study. The aim is to check on your health andsymptoms, check on your response to treatment and any side effects, and assess the study drug.This study will compare the study drug with either mepolizumab or benralizumab, known as the comparator medications. The effects of the drugs, both good and bad, will be compared. Study participants will be divided into 2 groups to receive:Study drug (once every 26 weeks) + placebo (once every 4 or 8 weeks) OR,Mepolizumab (once every 4 weeks) or benralizumab (once every 8 weeks) + placebo (once every 26 weeks).All participants will receive an active treatment. You will be assigned to receive either the study drug or comparator (mepolizumab or benralizumab) you were taking before the study. No participant previouslytaking mepolizumab will be assigned to benralizumab, and no participant previously taking benralizumab will be assigned to mepolizumab.
$183.00
Have a documented diagnosis of asthma for 2 or more years.
Receiving either mepolizumab or benralizumab for 12 or more months prior to screening.
A well-documented requirement for regular treatment with medium to high dose inhaled corticosteroid in the 12 months prior to Visit 1 with or without maintenance oral corticosteroid.
Current treatment with at least one additional controller medication, besides an inhaled corticosteroids.
Eosinophilic diseases
Pregnancy
Current or former smokers with a smoking history of 10 or more years.
Active COVID-19 infection
Comparing Mechanisms of Pattern Learning
The purpose of the proposed plan of research is to investigate the types of patterns that human adults with or without a history of language/ learning difficulties tap into as they learn.
Our study involves an initial testing session lasting between 1-2 hours, followed by up to two additional sessions for eligible participants. As part of our study, you will take part in some speaking, listening, learning, and visual processing tasks.
up to $75
Only speaks English fluently
Normal or corrected-to-normal vision/ hearing
Minimum of high school education
May have a history of language/ learning difficulties
Speaks more than one language
Under age 18
Over age 28
Does not have minimum of high school education
Olfactory tools for COVID-19 screening and surveillance
This a collaborative multisite NIH funded project to develop smell tests as a rapid low cost way to screen for Covid19 infections. The lead institution is the University of Florida, and this project is being entered into CATS to create a Reliance Agreement under the NIH single IRB rules (sIRB).
COVID19 negative
COVID19 positive
Able to Consent in English
History of known pre-existing olfactory or taste disorder
History of head trauma with loss of consciousness
History of neurodegenerative disease
Adapting Perceptual Models and Haptic Encodings in Wearable Tactile Interfaces to Support Motor Learning
The purpose of this study is to determine how accurately a person can follow movement instructions indicated using vibrations on the skin and squeezing around the arm. Specifically, we will evaluate how this accuracy changes when a person is moving with a robotic arm.
There will be a single in-person session. You will be asked to first complete a short survey about activities that utilize a large amount of hand-eye coordination. After completing the survey, you will have an armband with vibration motors and a squeeze band fitted to your right arm. You will complete repetitions of a timed point-to-point reaching task. The vibration motors and squeeze band will be used to indicate the required motions to complete the point-to-point reaching task.
20 dollars
Normal Upper-Limb Function
Right-Handed
Illness affecting upper-limb function
Filling a Gap in Counseling Services for People with Aphasia: The Effects of an Online Training for Healthcare Providers
The purpose of the proposed study is to improve counseling services for people with aphasia. We will examine the effects of a brief training for speech-language pathologists (SLP) and rehabilitation counselors on therapeutic quality and behavioral outcomes for persons with aphasia.
English speaker
normal or corrected-to-normal hearing
self-reported need for mental health services (e.g., grief and loss, social isolation, depression, anxiety)
medically stable
severe mental health concerns (e.g., suicidal thoughts, self-harm, drug and alcohol abuse)
Human-robot interaction study
We are interested in developing robots that can interact with humans. We hope that to develop robots that can interact with people and be used in a variety of different situations such as schools, offices, and homes. This study investigates human-robot interaction.
Collecting Data for Human Confusion When Following Simulated Robot’s Instructions
We seek to try to try to create robots that recognize when people are confused. To do that, we need to collect data related to confusion. We are thus going to present confusing stimuli to people and record their facial expression.
US resident
Non-US resident
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)
This is a study that will compare a study drug pembrolizumab plus a study drug lenvatinib in combination with the therapy called TACE (transarterial chemoembolization) which is a way to deliver chemotherapy locally through a procedure called embolization and how that works versus placebo (or no study medications) plus TACE and how it could lead to progression-free survival (PFS).
This is a study that will compare a study drug pembrolizumab plus a study drug lenvatinib in combination with the therapy called TACE (transarterial chemoembolization) which is a way to deliver chemotherapy locally through a procedure called embolization and how that works versus placebo (or no study medications) plus TACE and how it could lead to progression-free survival (PFS).
Has HCC localized to the liver without portal vein thrombosis, and not amenable to curative treatment such as resection, ablation, or liver transplant.
Has at least one measurable HCC lesion based on RECIST 1.1,
Has an ECOG performance score of 0 to 1
Has a predicted life expectancy of >3 months.
Has had esophageal or gastric variceal bleeding within the last 6 months.
Has clinically apparent ascites on physical examination that is not controlled with medication
Has had clinically diagnosed hepatic encephalopathy in the last 6 months unresponsive to therapy.
Has clinically significant hemoptysis from any source or tumor bleeding within 2 weeks prior
Healthy Mom Zone: Control Systems Engineering for Optimizing a Prenatal Weight Gain Intervention Study 2.0
The proposed overall research aims to establish feasibility of delivering an individually-tailored, behavioral intervention to manage gestational weight gain [GWG] that adapts to the unique needs and challenges of overweight/obese pregnant women [OW/OB-PW] and will utilize control systems engineering to optimize this intervention; in other words, make this intervention manage GWG in OW/OB-PW as effectively and efficiently as possible.
You will be randomized into an intervention or attention control group from ~8 weeks gestation to ~37 weeks gestation with a BMI of 25-45 (>40 with physician consent).You will have 1 pre-intervention session that explains the study procedures and to get you ready for the study. Here you will also complete various measures of demographics, behavioral surveys, etc.Over the course of the study, you will weigh yourself each day, wear an activity monitor and complete various surveys. If you are randomized to the intervention group, you may have healthy eating demonstrations and/or physical activity sessions each week.You will have 1 post-intervention session where you will return your devices, complete a 30-60 minute interview and complete the last of the surveys.
$175
Women
18-45
English speaking
BMI 25-45 (>40 with provider consent)
Men
Younger than 18
Non-English speaking
BMI <25
Brain Mechanisms of Overeating in Children
Reducing intake from large portions is of critical importance to preventing obesity. People consistently eat more when they are served larger portions, a phenomenon known as the portion size effect. The mechanisms of the portion size effect are not well understood, and investigating the underlying neurobiology that drives this phenomenon may inform the development of more effective obesity prevention programs. The proposed research will follow healthy weight children who vary by family risk for obesity to identify the neurobiological and appetitive traits that are implicated in overeating and weight gain during the critical pre-adolescent period. We expect results to confirm the hypothesis that reduced function of brain inhibitory pathways and increased activity in brain reward pathways in response to portion size cues contributes to excess intake with large portions and greater weight gain over time, particularly in children who have higher risk for obesity. The proposed studies will characterize the relationship between brain response to portion size and eating behavior and will allow us to determine whether brain and behavioral responses predict body fat gain during pre-adolescence. These studies will contribute essential information to our understanding of the pathways implicated in overeating and obesity and will facilitate the characterization of “at risk” phenotypes that can be targeted by prevention programs.
There will be seven in person visits with two DEXA measurements, one fMRI scan and five meals.
$350
The child must not have any food allergies to foods used in the study, learning disabilities, psychological diagnoses, red/green color blindness, or claustrophobia.
The child must not be taking any medications known to influence cognitive function, taste, appetite or blood flow
The child's BMI must be below the 90th percentile at the first visit
The biological mother and father must have a BMI between 18.5-25 kg/m2 (low-risk group) or greater than or equal to 30 kg/m2 for mothers and greater than or equal to 25 kg/m2 for fathers (high-risk group) and 1 parent must attend all visits.
Children will be excluded if they have any food allergies, learning disabilities, psychological diagnoses, red/green color blindness, or claustrophobia
Children will be excluded if they are taking cold or allergy medication, or other medications known to influence cognitive function, taste, appetite, or blood flow
Children will be excluded if their BMI is above the 90th percentile at the first visit
Families will be excluded if the biological mother or father do not fit the BMI requirements
NRG-GI008 Colon Adjuvant Chemotherapy based on Evaluation of Residual Disease (CIRCULATE-US) (22-070)
To compare time to ctDNA (+ve) status in ctDNA (-ve) cohort following resection of stage III colon cancer treated with immediate vs delayed (based on serial ctDNA surveillance) chemotherapy. Time to positive event is defined as time from randomization to the first ctDNA positive result for the immediate arm (Arm 1) and to the 2nd ctDNA positive result for the delayed arm (Arm 2) to allow for the potential effect of delayed adjuvant chemotherapy. Patients recurred without a positive ctDNA result will be considered to have ctDNA positive status at the time of recurrence for both study arms.
We are asking you to take part in this research study because you have colon cancer that has been treated with surgery but has spread to some of your lymph nodes and is known as stage III colon cancer. Or, you have stage II or stage III colon cancer with a higher risk of cancer returning, your colon cancer has been treated with surgery, and you had ctDNA testing done and are ctDNA positive. Stage II colon cancer is an early stage colon cancer that has been treated with surgery but has not spread to your lymph nodes. ctDNA, or circulating tumor DNA, is DNA that has been released from tumor cells into your bloodstream. This DNA can be measured using a blood test.
Hemoglobin must be ≥ 9 g/dL
HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months
The treating investigator must deem the patient a candidate for all potential agents used in this trial (5FU, LV, oxaliplatin and irinotecan)
The patient must have an ECOG performance status of 0 or 1
Tumor-related bowel perforation
Synchronous primary rectal and/ or colon cancers
Active seizure disorder uncontrolled by medication
Active or chronic infection requiring systemic therapy
Examining elderly traumatic brain injury and risk for neurodegeneration
The purpose of this proposal is to understand the risk factors for Alzheimer’s disease after TBI, including time since diagnosis, ethnicity, and genetic predictors. In Aim 1 the goal is to collect data in a large group of individuals with TBI to understand these interacting factors in predicting cognitive decline. Then in Aim 2, in a sub-group of individuals we use brain imaging methods in order to determine the network response associated with neurodegeneration decades post TBI. Ultimately, the ability to monitor the neural network response to injury-specific factors in combination with risk/resiliency factors (e.g., genetic, health) may bring greater precision to rehabilitation in TBI and aid in identifying patients at risk for neurodegeneration years prior to onset. Three specific aims were designed to clarify the role of neural recruitment in recovery from TBI:
There will be one in person visit that lasts ~5 hours. It involves an MRI scan, blood pressure measurement, cognitive testing, and interviews about social and emotional wellbeing.
$150
sustained a traumatic brain injury
history of neurological disorder such as stroke, epilepsy, or multiple sclerosis
history of bipolar
Pregnant or trying to become pregnant
Investigation of pulse starch impact on the gut microbiome
We are investigating how the starch from pulse crops (chickpeas, lentils and dry peas) affects the gut microbiome, particularly with regards to the production of butyrate, a microbial metabolite with a number of known health benefits. We are recruiting people from two groups, those that consume a lot of these pulses and those who rarely consume them. These participants will then track their food intake for 48 hours before collecting a fecal sample which they will return to the lab. We will then use these fecal samples to conduct laboratory fermentations with pulse starches processed in a number of different ways to see what factors are important for determining the amount of butyrate that is produced. This will serve as pilot data for designing future human clinical trials.
Either consume pulses twice or more per week or consume them once a month or less. Pulses are dry legumes such as chickpeas(Garbanzo beans), lentils or other dry peas and beans
Taking a fiber supplement
Bowel problems such as IBD, IBS, chronic diarrhea or constipation
Pregnancy
Measuring the impact of three types of resistant starch on fecal butyrate levels and the gut microbiome in healthy and obese individuals
This is dietary intervention trial that will examine the impact of consuming three different types of resistant starch on the gut microbiome and butyrate levels in normal weight and obese individuals. Participants will consume starch samples daily for 24 weeks, collecting weekly fecal samples that will be returned to the lab. Researchers will analyze the bacterial fermentation products in these samples, particularly butyrate and analyze the microbiome composition. This will allow identification of differences in resistant starch (a dietary fiber) processing between normal weight and obese individuals and will also determine if the three resistant starches tested have differing impacts on the microbiome and butyrate levels.
Diagnosis of Diabetes
Pregnant
Taking antibiotics
A Multicenter, Open-Label, Single Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis: Open Label, 64 weeks study. Injectable medicine. Males/Females 2-11 years with moderate to severe atopic dermatitis. The goal of the study is assess the uptake of the drug by the body and safety of nemolizumab administered with topical corticosteroids.
Participants will attend in person visit at the Dermatology Clinical Trial office. Dr. Zaenglein is the pediatric dermatologist in charge of this research study and will do all skin evaluations. In addition at different time points there will be blood that is drawn, questionnaires to be completed, and ECGs will be performed.
Study coordinator will discuss.
Diagnosed with Moderate to Severe Atopic Dermatitis
Willing to attend all study visits and follow directions
Had a documented asthma exacerbation requiring hospitalization in the past 12 months.
Weigh less than 22 pounds
Effects of fasting on blood protein levels
Up to 50 older adults (age 60+ years) will participate in a two-visit CRC study with blood sampling (40 ml per visit) occurring before and after a breakfast meal. Specifically, there will be four (10 ml) blood draws during each of the visits, with each blood draw timed one hour apart (T1 to T4). The two visits (short- and long-fasting) will be randomly assigned and counterbalanced for the order in which they occur and will occur at least a week apart. During the short-fasting visit, participants will arrive fasting and be given breakfast after the second blood draw (T2). During the long-fasting visit, participants will arrive fasting and be given breakfast after the fourth blood draw (T4). Aside from blood draws, and vitals obtained at the start of each visit, participants will be seated comfortably in a chair in a small room by themselves. They will be checked upon periodically to ensure they are not falling asleep, they are comfortable, etc. They will also be given a small packet of written questionnaires to complete after T1 and after T3 (i.e., after the 1st and 3rd blood draws). Each visit will be between 3.5 and 4 hours.
There will be two in-person visits both will include four blood draws.
$100 total
Fluent in English
Vaccinated for COVID-19
Having current severe psychiatric symptoms that interfere with testing
Alcohol or substance abuse, chronic medicinal use of opioids, glucocorticoids, anti-inflammatories, or active cancer treatment in the last 12 months